Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mechanisms of Ozone-Induced Alterations in Efferocytosis and Phagocytosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03646877
Recruitment Status : Recruiting
First Posted : August 24, 2018
Last Update Posted : March 7, 2019
Sponsor:
Collaborators:
National Institutes of Health (NIH)
East Carolina University
Information provided by (Responsible Party):
Robert Tighe, MD, Duke University

Brief Summary:

The purpose of this research study to understand how environmental and genetic factors may be involved in lung function. Healthy Study participants will undergo a 1-day screening that includes a blood draw and breathing testing, return for a two-day series of testing to include blood draw, and brief breathing test before and after an inhaled challenge with either filtered air (FA) or ozone (O3). Participants return the next day for a brief breathing test, a blood draw and a procedure called bronchoscopy performed under conscious sedation to evaluate the lung after the challenge.

Participants then return 18 - 20 days later to repeat the two-day series of testing to be challenged with the exposure not received on the first series, (FA or O3). Each visit will take about 3 - 3.5 hours. Follow-up phone calls from the study team will occur at 24 hours after each 2-day test series. Total study duration is about one to one-and a half months.


Condition or disease Intervention/treatment Phase
Healthy Drug: Ozone Other: Filtered Air Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Mechanisms of Ozone-Induced Alterations in Efferocytosis and Phagocytosis
Actual Study Start Date : February 19, 2019
Estimated Primary Completion Date : January 31, 2024
Estimated Study Completion Date : January 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ozone

Arm Intervention/treatment
Experimental: Ozone (O3) Drug: Ozone
Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).

Placebo Comparator: Filtered Air (FA) Other: Filtered Air
Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.




Primary Outcome Measures :
  1. change in ozone induced efferocytosis of lung macrophages (ability to clear dead or dying cells) [ Time Frame: Baseline, 21 days ]
    Efferocytosis is defined by determining the number of apoptotic PMNs phagocytized by alveolar macrophages (BAL cytospins) versus the total number of macrophages ('efferocytic index')

  2. Change in ozone induced phagocytosis of lung macrophages (ability to clear debris or bacteria) [ Time Frame: Baseline, 21 days ]
    Bronchoalveolar macrophages are incubated with pHrodo™ dye-labeled particles. Macrophage phagocytosis will be defined by determining the number of macrophages that contain fluorescent particles versus the total macrophages Cell free hemoglobin and soluble CD163 - both are measured by commercial ELISA kit


Secondary Outcome Measures :
  1. Change in ozone induced increase in cell free hemoglobin in bronchoalveolar lavage fluid and serum [ Time Frame: Baseline, 21 days ]
    Measured by enzyme-linked immunosorbent assay (ELISA)

  2. Change in ozone induced increase in soluble CD163 in bronchoalveolar lavage fluid and serum [ Time Frame: Baseline, 21 days ]
    Measured by enzyme-linked immunosorbent assay (ELISA)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

• Individuals between 18-35 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)

Exclusion Criteria

  • Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years
  • Pregnant women and women who are presently lactating.
  • Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks
  • College and graduate students or employees who are under direct supervision by any of the investigators in this protocol
  • Alcohol or illicit substance abuse
  • Chronic cardio/pulmonary respiratory disorders or other medical conditions as determined by the investigator
  • Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 < 8 mg/ml)
  • Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03646877


Contacts
Layout table for location contacts
Contact: Catherine Foss 919-613-7627 catherine.foss@dm.duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Matt Kummerer, RN       matthew.kummerer@duke.edu   
Contact: Catherine Foss    919-479-0861    catherine.foss@dm.duke.edu   
Principal Investigator: Robert Tigher, MD         
Sponsors and Collaborators
Robert Tighe, MD
National Institutes of Health (NIH)
East Carolina University
Investigators
Layout table for investigator information
Principal Investigator: Robert Tighe, MD Duke University

Layout table for additonal information
Responsible Party: Robert Tighe, MD, Assistant Professor of Medicine, Duke University
ClinicalTrials.gov Identifier: NCT03646877     History of Changes
Other Study ID Numbers: PRO00100375
First Posted: August 24, 2018    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No